- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Innovative Approaches by Pharmacists Save Costs at a Comprehensive Cancer Center
Active implementation of cost-saving measures successfully cut down expenditure at the Norris Comprehensive Cancer Center.
In April 2012, the University of Southern California (USC) Norris Comprehensive Cancer Center in Pasadena opened a hospital-based, outpatient oncology infusion center, where clinical pharmacists have been key in developing cost-savings and cost-avoidance initiatives. From formulary management alone, pharmacists have saved close to $550,000 in one year.
Much of the savings were made possible by the infusion center’s designation as a 1206D facility, according to Betty M. Chan, PharmD, BCOP, an assistant professor of clinical pharmacy at Norris. The designation, which is unique to the state of California, exempts hospital-based practices from drug-pricing regulations and other rules that affect physician-based clinics. As a result, facilities with the 1206D designation benefit from improved reimbursement in the outpatient setting, Dr. Chan said. Other advantages include split billing, minimal staffing requirements and shared medical resources between affiliated clinics and hospitals.
Read the report here: http://bit.ly/1pSN0at
Source: Pharmacy Practice News
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
